Jennifer Rosenbluth, MD, PhD
Assistant Professor
Medicine
School of Medicine

Jennifer Rosenbluth, MD, PhD, is a medical oncologist who specializes in breast cancer, an Assistant Professor in the Department of Medicine, and a member of the Breast Oncology Program in the Helen Diller Family Comprehensive Cancer Center. The research in her laboratory utilizes three-dimensional organoid cultures of premalignant and tumorigenic breast tissues to identify heterogeneous populations of cells that promote cancer development and progression.

Awards

Show all (13) Hide

• Investigator Award, Chan Zuckerberg Biohub, 2022
• Young Investigator Grant, Breast Cancer Alliance, 2021
• Clinical Scientist Development Award, Doris Duke Charitable Foundation, 2021
• Fellowship Award, Terri Brodeur Breast Cancer Foundation, 2021
• Sulochana Pradhan, MD Endowed Professorship in Breast Cancer, UCSF, 2021
• Sidney Farber Scholar, Dana-Farber Cancer Institute, 2020-2021
• Eleanor and Miles Shore Award, Dana-Farber Cancer Institute, 2019-2020
• Career Catalyst Research Grant, Susan G. Komen Foundation, 2019
• Postdoctoral Fellowship, American Cancer Society, 2017-2019
• Young Investigator Award, American Society of Clinical Oncology, 2017-2018
• Leadership Council Fellow, Dana-Farber Cancer Institute, 2014
• Dean's Award for Research, Vanderbilt University, 2011
• John G. Coniglio Prize for Excellence in Biochemistry, Vanderbilt University, 2011

Education & Training

Show all (5) Hide

• Medical Oncology Dana-Farber Cancer Institute
• Internal Medicine Massachusetts General Hospital
• AB Princeton University
• MD Vanderbilt University School of Medicine
• PhD Vanderbilt University School of Medicine

Websites

Show all (1) Hide

• lab website (Rosenbluthlab.ucsf.edu)

Publications (23)

Top publication keywords:
Nuclear ProteinsCell Culture TechniquesCarcinoma, Ductal, BreastInflammatory Breast NeoplasmsOrganoidsGenes, Tumor SuppressorCross ReactionsTumor Suppressor ProteinsMammary Glands, HumanProtein KinasesCell LineageAntibody SpecificityTOR Serine-Threonine KinasesTumor Protein p73DNA-Binding Proteins

• A human breast atlas integrating single-cell proteomics and transcriptomics.
  Developmental cell 2022 Gray GK, Li CM, Rosenbluth JM, Selfors LM, Girnius N, Lin JR, Schackmann RCJ, Goh WL, Moore K, Shapiro HK, Mei S, D'Andrea K, Nathanson KL, Sorger PK, Santagata S, Regev A, Garber JE, Dillon DA, …
• Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids.
  Nature protocols 2021 Dekkers JF, van Vliet EJ, Sachs N, Rosenbluth JM, Kopper O, Rebel HG, Wehrens EJ, Piani C, Visvader JE, Verissimo CS, Boj SF, Brugge JS, Clevers H, Rios AC
• Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages.
  Nature communications 2020 Rosenbluth JM, Schackmann RCJ, Gray GK, Selfors LM, Li CM, Boedicker M, Kuiken HJ, Richardson A, Brock J, Garber J, Dillon D, Sachs N, Clevers H, Brugge JS
• Inflammatory Breast Cancer: a Separate Entity.
  Current oncology reports 2019 Rosenbluth JM, Overmoyer BA
• Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade.
  Clinical breast cancer 2018 Jacene HA, Youn T, DiPiro PJ, Hu J, Cheng SC, Franchetti Y, Shah H, Bellon JR, Warren L, Schlosnagle E, Nakhlis F, Rosenbluth J, Yeh E, Overmoyer B, Dana-Farber Cancer Institute Inflammatory Breast …
• Differential regulation of the p73 cistrome by mammalian target of rapamycin reveals transcriptional programs of mesenchymal differentiation and tumorigenesis.
  Proceedings of the National Academy of Sciences of the United States of America 2011 Rosenbluth JM, Mays DJ, Jiang A, Shyr Y, Pietenpol JA

Show all (17 more) Hide

• Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer.
  NPJ breast cancer 2023 Garrido-Castro AC, Regan MM, Niman SM, Nakhlis F, Remolano C, Rosenbluth JM, Block C, Warren LE, Bellon JR, Yeh E, Harrison BT, Troll E, Lin NU, Tolaney SM, Overmoyer B, Lynce F
• Implantation of engineered adipocytes that outcompete tumors for resources suppresses cancer progression.
  bioRxiv : the preprint server for biology 2023 Nguyen HP, Sheng R, Murray E, Ito Y, Bruck M, Biellak C, An K, Lynce F, Dillon DA, Magbanua MJM, Huppert LA, Hammerlindl H, Esserman L, Rosenbluth JM, Ahituv N
• Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
  Cancer research communications 2022 Glencer AC, Miller PN, Greenwood H, Maldonado Rodas CK, Freimanis R, Basu A, Mukhtar RA, Brabham C, Kim P, Hwang ES, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky AD, Esserman LJ
• Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast Cancer.
  American journal of clinical oncology 2021 Hirko KA, Regan MM, Remolano MC, Schlossman J, Harrison B, Yeh E, Jacene H, Nakhlis F, Block C, Rosenbluth JM, Garrido-Castro AC, Overmoyer BA
• Aging-Associated Alterations in Mammary Epithelia and Stroma Revealed by Single-Cell RNA Sequencing.
  Cell reports 2020 Li CM, Shapiro H, Tsiobikas C, Selfors LM, Chen H, Rosenbluth J, Moore K, Gupta KP, Gray GK, Oren Y, Steinbaugh MJ, Guerriero JL, Pinello L, Regev A, Brugge JS
• Characteristics associated with inflammatory breast cancer (IBC): An epidemiologic study from a dedicated IBC program.
  The breast journal 2020 White RE, Warren L, Nakhlis F, Rosenbluth J, Bellon J, Block C, Overmoyer B
• Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning.
  Breast cancer research and treatment 2020 Jacene HA, DiPiro PJ, Bellon J, Hu J, Cheng SC, Warren L, Schlosnagle E, Nakhlis F, Rosenbluth JM, Yeh E, Overmoyer B
• A large peptidome dataset improves HLA class I epitope prediction across most of the human population.
  Nature biotechnology 2019 Sarkizova S, Klaeger S, Le PM, Li LW, Oliveira G, Keshishian H, Hartigan CR, Zhang W, Braun DA, Ligon KL, Bachireddy P, Zervantonakis IK, Rosenbluth JM, Ouspenskaia T, Law T, Justesen S, Stevens J, …
• Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion.
  Cell metabolism 2019 Harris IS, Endress JE, Coloff JL, Selfors LM, McBrayer SK, Rosenbluth JM, Takahashi N, Dhakal S, Koduri V, Oser MG, Schauer NJ, Doherty LM, Hong AL, Kang YP, Younger ST, Doench JG, Hahn WC, Buhrlage …
• A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Jovanovic B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, …
• p73 Is Required for Multiciliogenesis and Regulates the Foxj1-Associated Gene Network.
  Cell reports 2016 Marshall CB, Mays DJ, Beeler JS, Rosenbluth JM, Boyd KL, Santos Guasch GL, Shaver TM, Tang LJ, Liu Q, Shyr Y, Venters BJ, Magnuson MA, Pietenpol JA
• ISG20L1 is a p53 family target gene that modulates genotoxic stress-induced autophagy.
  Molecular cancer 2010 Eby KG, Rosenbluth JM, Mays DJ, Marshall CB, Barton CE, Sinha S, Johnson KN, Tang L, Pietenpol JA
• Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Bauer JA, Chakravarthy AB, Rosenbluth JM, Mi D, Seeley EH, De Matos Granja-Ingram N, Olivares MG, Kelley MC, Mayer IA, Meszoely IM, Means-Powell JA, Johnson KN, Tsai CJ, Ayers GD, Sanders ME, …
• Evaluation of p63 and p73 antibodies for cross-reactivity.
  Cell cycle (Georgetown, Tex.) 2009 Rosenbluth JM, Johnson K, Tang L, Triplett T, Pietenpol JA
• mTOR regulates autophagy-associated genes downstream of p73.
  Autophagy 2009 Rosenbluth JM, Pietenpol JA
• The jury is in: p73 is a tumor suppressor after all.
  Genes & development 2008 Rosenbluth JM, Pietenpol JA
• A gene signature-based approach identifies mTOR as a regulator of p73.
  Molecular and cellular biology 2008 Rosenbluth JM, Mays DJ, Pino MF, Tang LJ, Pietenpol JA